Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:physicist
|
| gptkbp:activeDuring |
idursulfase
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:clinicalTrials |
Phase III
long-term treatment Adult Study Efficacy and Safety Study Long-term Safety Study Pediatric Study included_in_treatment_guidelines_for_Hunter_syndrome |
| gptkbp:community_service |
Shire's_patient_support_program
|
| gptkbp:contraindication |
fatigue
muscle pain urticaria joint pain chills anaphylaxis angioedema hypersensitivity_to_idursulfase |
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
half-life of approximately 2 hours
increases enzyme levels limited drug interactions |
| gptkbp:formulation |
sterile solution
|
| gptkbp:hasPopulation |
children and adults
|
| gptkbp:healthcare |
important for treatment efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Elaprase
|
| gptkbp:impact |
lifelong treatment
|
| gptkbp:is_monitored_by |
regular monitoring required
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2006
|
| gptkbp:mandates |
treatment of mucopolysaccharidosis II
|
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
high cost of treatment
|
| gptkbp:packaging |
single-use vials
|
| gptkbp:regulatoryCompliance |
orphan_drug_designation
|
| gptkbp:relatedPatent |
genetic disorders
metabolic disorders lysosomal storage disorders |
| gptkbp:researchFocus |
mucopolysaccharidosis
|
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
headache
nausea fever vomiting rash infusion reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:supplyChain |
cold chain logistics
|
| gptkbp:triggerType |
replaces iduronate-2-sulfatase
|
| gptkbp:usedFor |
gptkb:Hunter_syndrome
|